局部晚期和转移性唾液腺癌的治疗:葡萄牙肿瘤中心的10年经验。

IF 1 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
Ana Raquel Teixeira, Cláudia Agostinho, Catarina Dias, Rita Soares, Marta Pina, José Dinis, Luísa Lopes-Conceição, Cláudia Vieira
{"title":"局部晚期和转移性唾液腺癌的治疗:葡萄牙肿瘤中心的10年经验。","authors":"Ana Raquel Teixeira, Cláudia Agostinho, Catarina Dias, Rita Soares, Marta Pina, José Dinis, Luísa Lopes-Conceição, Cláudia Vieira","doi":"10.20344/amp.22800","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Scientific evidence regarding salivary gland cancer systemic treatment is limited and the therapeutic approach to locally advanced or metastatic disease is mainly based on consensus. This study aimed to evaluate treatment patterns and outcomes in patients with advanced salivary gland cancer.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study in a comprehensive cancer center in Portugal, including adult patients diagnosed with primary malignant salivary gland tumors between 2012 and 2021. Data on demographics, tumor characteristics, treatments, and outcomes were collected from institutional cancer registries and electronic medical records. The study was approved by the institutional Ethics Committee.</p><p><strong>Results: </strong>A total of 116 patients with salivary gland cancer were identified and, of these, 45 had locally advanced or metastatic disease: 24 received systemic anti-neoplastic treatment and 21 received best supportive care. One-year overall survival in systemic anti-neoplastic treatment group was 70% (versus 14% in best supportive care group, p < 0.001) and progression-free survival was 37%. The most commonly used systemic treatment was chemotherapy (n = 29, 59%). Seven patients (14%) received androgen deprivation therapy, and two patients (4%) received other targeted therapy (olaparib and erdafitinib).</p><p><strong>Conclusion: </strong>Systemic treatment was associated with significantly improved survival in patients with advanced salivary gland cancer. Despite the heterogeneity of therapeutic approaches, including emerging biomarker-driven therapies, clinical decision-making remains largely consensus-based. These findings underscore the need for further research to support personalized treatment strategies and guide evidence-based care.</p>","PeriodicalId":7059,"journal":{"name":"Acta medica portuguesa","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of Locally Advanced and Metastatic Salivary Gland Cancer: A 10-year Experience of an Oncology Center in Portugal.\",\"authors\":\"Ana Raquel Teixeira, Cláudia Agostinho, Catarina Dias, Rita Soares, Marta Pina, José Dinis, Luísa Lopes-Conceição, Cláudia Vieira\",\"doi\":\"10.20344/amp.22800\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Scientific evidence regarding salivary gland cancer systemic treatment is limited and the therapeutic approach to locally advanced or metastatic disease is mainly based on consensus. This study aimed to evaluate treatment patterns and outcomes in patients with advanced salivary gland cancer.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study in a comprehensive cancer center in Portugal, including adult patients diagnosed with primary malignant salivary gland tumors between 2012 and 2021. Data on demographics, tumor characteristics, treatments, and outcomes were collected from institutional cancer registries and electronic medical records. The study was approved by the institutional Ethics Committee.</p><p><strong>Results: </strong>A total of 116 patients with salivary gland cancer were identified and, of these, 45 had locally advanced or metastatic disease: 24 received systemic anti-neoplastic treatment and 21 received best supportive care. One-year overall survival in systemic anti-neoplastic treatment group was 70% (versus 14% in best supportive care group, p < 0.001) and progression-free survival was 37%. The most commonly used systemic treatment was chemotherapy (n = 29, 59%). Seven patients (14%) received androgen deprivation therapy, and two patients (4%) received other targeted therapy (olaparib and erdafitinib).</p><p><strong>Conclusion: </strong>Systemic treatment was associated with significantly improved survival in patients with advanced salivary gland cancer. Despite the heterogeneity of therapeutic approaches, including emerging biomarker-driven therapies, clinical decision-making remains largely consensus-based. These findings underscore the need for further research to support personalized treatment strategies and guide evidence-based care.</p>\",\"PeriodicalId\":7059,\"journal\":{\"name\":\"Acta medica portuguesa\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta medica portuguesa\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.20344/amp.22800\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica portuguesa","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20344/amp.22800","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

关于唾液腺癌全身治疗的科学证据有限,局部晚期或转移性疾病的治疗方法主要基于共识。本研究旨在评估晚期唾液腺癌患者的治疗模式和结果。方法:我们在葡萄牙的一家综合癌症中心进行了一项回顾性队列研究,纳入了2012年至2021年间诊断为原发性恶性唾液腺肿瘤的成年患者。有关人口统计学、肿瘤特征、治疗和结果的数据收集自机构癌症登记和电子医疗记录。该研究得到了机构伦理委员会的批准。结果:共有116例涎腺癌患者被确定,其中45例为局部晚期或转移性疾病,24例接受了全身抗肿瘤治疗,21例接受了最佳支持治疗。全身抗肿瘤治疗组的1年总生存率为70%(最佳支持治疗组为14%,p < 0.001),无进展生存率为37%。最常用的全身治疗是化疗(n = 29, 59%)。7例患者(14%)接受了雄激素剥夺治疗,2例患者(4%)接受了其他靶向治疗(奥拉帕尼和厄达非替尼)。结论:全身治疗可显著提高晚期唾液腺癌患者的生存率。尽管治疗方法存在异质性,包括新兴的生物标志物驱动疗法,但临床决策仍然主要基于共识。这些发现强调了进一步研究以支持个性化治疗策略和指导循证护理的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment of Locally Advanced and Metastatic Salivary Gland Cancer: A 10-year Experience of an Oncology Center in Portugal.

Introduction: Scientific evidence regarding salivary gland cancer systemic treatment is limited and the therapeutic approach to locally advanced or metastatic disease is mainly based on consensus. This study aimed to evaluate treatment patterns and outcomes in patients with advanced salivary gland cancer.

Methods: We conducted a retrospective cohort study in a comprehensive cancer center in Portugal, including adult patients diagnosed with primary malignant salivary gland tumors between 2012 and 2021. Data on demographics, tumor characteristics, treatments, and outcomes were collected from institutional cancer registries and electronic medical records. The study was approved by the institutional Ethics Committee.

Results: A total of 116 patients with salivary gland cancer were identified and, of these, 45 had locally advanced or metastatic disease: 24 received systemic anti-neoplastic treatment and 21 received best supportive care. One-year overall survival in systemic anti-neoplastic treatment group was 70% (versus 14% in best supportive care group, p < 0.001) and progression-free survival was 37%. The most commonly used systemic treatment was chemotherapy (n = 29, 59%). Seven patients (14%) received androgen deprivation therapy, and two patients (4%) received other targeted therapy (olaparib and erdafitinib).

Conclusion: Systemic treatment was associated with significantly improved survival in patients with advanced salivary gland cancer. Despite the heterogeneity of therapeutic approaches, including emerging biomarker-driven therapies, clinical decision-making remains largely consensus-based. These findings underscore the need for further research to support personalized treatment strategies and guide evidence-based care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta medica portuguesa
Acta medica portuguesa MEDICINE, GENERAL & INTERNAL-
CiteScore
1.90
自引率
16.70%
发文量
256
审稿时长
6-12 weeks
期刊介绍: The aim of Acta Médica Portuguesa is to publish original research and review articles in biomedical areas of the highest standard, covering several domains of medical knowledge, with the purpose to help doctors improve medical care. In order to accomplish these aims, Acta Médica Portuguesa publishes original articles, review articles, case reports and editorials, among others, with a focus on clinical, scientific, social, political and economic factors affecting health. Acta Médica Portuguesa will be happy to consider manuscripts for publication from authors anywhere in the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信